Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
Pharma News, 2025
HHS launches $500m universal vaccines initiative
The US Department of Health and Human Services (HHS) has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with pandemic potential, including in...
FDA awards RMAT status to 4DMT diabetic macular oedema therapy
4D Molecular Therapeutics (4DMT) has received regenerative medicine advanced therapy (RMAT) designation from the US Food and Drug Administration (FDA) for 4D-150 for diabetic m...
Avutometinib Combo Shows Activity, Safety for HR+/HER2- Breast Cancer
The combination of avutometinib (VS-6766), abemaciclib (Verzenio), and fulvestrant (Faslodex) showed a manageable safety profile and early signs of efficacy in patients with ho...
FDA Clears IND Application for TROP-2 Targeting ADC in Solid Tumors
The FDA has cleared an investigational new drug (IND) application for the TROP-2 targeted antibody drug conjugate (ADC), OBI-902, to conduct a phase 1/2 study in patients with solid tu...
Scientists at the University of East Anglia (UEA) have developed a revolutionary new way
Scientists at the University of East Anglia (UEA) have developed a revolutionary new way of uncovering the 'true age' of your heart using MRI
Dimerix and Amicus to commercialise DMX-200 in US
Australian biopharmaceutical company Dimerix and Amicus Therapeutics have signed an agreement for the US commercialisation of the former’s Phase III drug candidate DMX-200.
Silo Pharma's SP-26
Silo Pharma's SP-26 Implant Achieves All Endpoints In Preclinical Fibromyalgia Study
NewAmsterdam Pharma
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
Boehringer, Oxford University and Cumulus to explore brain activity in BPD
Boehringer Ingelheim, the University of Oxford and Cumulus Neuroscience have launched a study to monitor brain activity in individuals with borderline personality disorder (BPD) using new tech...
Abeona cell therapy approved by FDA for rare skin condition
The Food and Drug Administration on Tuesday approved a new treatment for a rare skin condition, teeing up a commercial battle between two cell and gene therapy developers.
Nuvalent reveals preclinical data on cancer drug zidesamtinib
CAMBRIDGE, Mass. - Nuvalent, Inc., a clinical-stage biopharmaceutical company valued at $5.4 billion
Amgen to invest $900m in Ohio manufacturing facility
Amgen has announced a significant expansion of a manufacturing facility in the US state of Ohio, with an investment of $900m.
32
33
34
35
36
37
38
39
40
